ATE424413T1 - Analoge des glucagon-ähnlichen peptids-1 - Google Patents

Analoge des glucagon-ähnlichen peptids-1

Info

Publication number
ATE424413T1
ATE424413T1 AT06114553T AT06114553T ATE424413T1 AT E424413 T1 ATE424413 T1 AT E424413T1 AT 06114553 T AT06114553 T AT 06114553T AT 06114553 T AT06114553 T AT 06114553T AT E424413 T1 ATE424413 T1 AT E424413T1
Authority
AT
Austria
Prior art keywords
glucagone
analogue
peptide
Prior art date
Application number
AT06114553T
Other languages
English (en)
Inventor
Wolfgang Glaesner
Rohn Millican
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE424413T1 publication Critical patent/ATE424413T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
AT06114553T 2000-06-16 2001-06-01 Analoge des glucagon-ähnlichen peptids-1 ATE424413T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21217100P 2000-06-16 2000-06-16
US24034900P 2000-10-13 2000-10-13

Publications (1)

Publication Number Publication Date
ATE424413T1 true ATE424413T1 (de) 2009-03-15

Family

ID=26906843

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06114553T ATE424413T1 (de) 2000-06-16 2001-06-01 Analoge des glucagon-ähnlichen peptids-1
AT01939252T ATE346093T1 (de) 2000-06-16 2001-06-01 Analoge des glucagon ähnlichen peptid-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01939252T ATE346093T1 (de) 2000-06-16 2001-06-01 Analoge des glucagon ähnlichen peptid-1

Country Status (33)

Country Link
US (2) US7084243B2 (de)
EP (2) EP1695983B1 (de)
JP (1) JP4716641B2 (de)
KR (1) KR100847615B1 (de)
CN (1) CN100469791C (de)
AR (1) AR031701A1 (de)
AT (2) ATE424413T1 (de)
AU (2) AU6479101A (de)
BR (1) BR0111562A (de)
CA (1) CA2412004C (de)
CY (2) CY1105917T1 (de)
CZ (1) CZ304002B6 (de)
DE (2) DE60137876D1 (de)
DK (2) DK1695983T3 (de)
DZ (1) DZ3388A1 (de)
EA (1) EA008837B1 (de)
EG (1) EG24755A (de)
ES (2) ES2321439T3 (de)
HK (1) HK1055121A1 (de)
HR (1) HRP20020996B1 (de)
HU (2) HU229208B1 (de)
IL (2) IL153453A0 (de)
MX (1) MXPA02012203A (de)
MY (1) MY137350A (de)
NO (1) NO330686B1 (de)
NZ (1) NZ522330A (de)
PE (1) PE20011363A1 (de)
PL (1) PL206302B1 (de)
PT (2) PT1294757E (de)
SI (1) SI1695983T1 (de)
SK (1) SK287757B6 (de)
TW (1) TWI321134B (de)
WO (1) WO2001098331A2 (de)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2001000654A2 (en) 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
AU6479101A (en) * 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
AU2002213925A1 (en) * 2000-09-18 2002-03-26 Osteometer Biotech As Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
US7101843B2 (en) 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
NZ531788A (en) * 2001-10-18 2008-01-31 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
JP2005516968A (ja) * 2001-12-29 2005-06-09 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
MXPA04008068A (es) * 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
EP1894591B1 (de) 2002-03-20 2013-06-26 MannKind Corporation Kartusche für eine Inhalationsvorrichtung
US20060252916A1 (en) * 2002-06-04 2006-11-09 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
US8377869B2 (en) * 2007-10-24 2013-02-19 Mannkind Corporation Method of preventing adverse effects by GLP-1
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US8372804B2 (en) * 2007-10-24 2013-02-12 Mannkind Corporation Delivery of active agents
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004067548A2 (en) * 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
DE602004025205D1 (de) 2003-02-19 2010-03-11 Ipsen Pharma Glp-1-analoga
US7259234B2 (en) 2003-05-15 2007-08-21 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
ATE541582T1 (de) * 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
KR100758755B1 (ko) 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP1694278A4 (de) * 2003-12-16 2009-08-12 Ipsen Pharma Glp-1 pharmazeutische zusammensetzungen
JP2007536214A (ja) * 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１類似体
EP1709071A4 (de) * 2004-01-08 2007-05-30 Theratechnologies Inc Analoga des glucagon-like peptid-1 mit langer wirkungsdauer
EP2298901B2 (de) 2004-04-30 2017-04-26 Dow AgroSciences LLC Neuartige Herbizidresistenz-Gene
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
ES2540853T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
US8710181B2 (en) * 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
EP2330126B1 (de) 2004-10-07 2015-12-23 Novo Nordisk A/S Exendin-4-Zusammensetzungen mit verlängerter Halbwertszeit
EP2494983B1 (de) 2004-11-12 2019-04-24 Novo Nordisk A/S Stabile formulierung von glp-1
ES2541633T3 (es) 2005-01-14 2015-07-22 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Exendinas modificadas y usos de las mismas
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1864661A1 (de) * 2005-03-18 2007-12-12 Ajinomoto Co., Inc. Prophylaktisches/therapeutisches mittel gegen stressbedingte darmerkrankung
WO2006124529A1 (en) * 2005-05-13 2006-11-23 Eli Lilly And Company Glp-1 pegylated compounds
CN101258163B (zh) * 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
HUE052842T2 (hu) 2005-10-28 2021-05-28 Dow Agrosciences Llc Új herbicidrezisztencia-gének
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (zh) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 截短胰高血糖素样肽1(sGLP-1)、制法及其应用
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2008063203A2 (en) * 2006-01-27 2008-05-29 Whitehead Institute For Biomedical Research Compositions and methods for efficient gene silencing in plants
EP1986679B1 (de) 2006-02-22 2017-10-25 MannKind Corporation Verfahren zur verbesserung der pharmazeutischen eigenschaften von mikropartikeln mit diketopiperazin und einem wirkstoff
EP2573111A1 (de) 2006-04-20 2013-03-27 Amgen Inc. GLP-1-Verbindungen
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
CN101466398A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
CA2655923A1 (en) * 2006-07-06 2008-01-10 Amylin Pharmaceuticals, Inc. Glucagon-like peptides and uses thereof
AR061930A1 (es) 2006-07-18 2008-10-01 Centocor Inc Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
KR100851560B1 (ko) * 2006-12-27 2008-08-11 고려대학교 산학협력단 새로운 글루카곤 유사 펩타이드-1 (ｇｌｐ-1) 작용제 및 그용도
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CN101041693B (zh) * 2007-02-06 2011-08-17 珠海联邦制药股份有限公司 一种降血糖多肽及其应用
EA017849B1 (ru) 2007-02-15 2013-03-29 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соагонисты глюкагоновых/glp-1-рецепторов
AU2008244523B2 (en) * 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
GB2448895A (en) * 2007-05-01 2008-11-05 Activotec Spp Ltd GLP-1 like compounds and uses thereof
US8464239B2 (en) * 2007-06-11 2013-06-11 Red Hat, Inc. Real-time installation and/or configuration assistant
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2214691B1 (de) 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Verbindungen mit glucagon-antagonistischer und glp-1-agonistischer wirkung
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
PL2293833T3 (pl) 2008-06-13 2016-08-31 Mannkind Corp Inhalator proszkowy i układ do dostarczania leku
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
ES2650038T3 (es) 2008-06-17 2018-01-16 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
ES2579502T3 (es) 2008-06-17 2016-08-11 Indiana University Research And Technology Corporation Coagonistas de receptores de glucagón/GLP-1
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
EP3412300A1 (de) 2008-06-27 2018-12-12 Duke University Therapeutika mit elastinähnlichen peptiden
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
CN101337989B (zh) * 2008-08-28 2012-10-24 中国药科大学 一类新型胰高血糖素样肽-1(glp-1)类似物及其应用
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
DK2344519T3 (en) 2008-11-07 2017-01-23 Massachusetts Gen Hospital C-TERMINAL FRAGMENTS OF GLUCAGON SIMILAR PEPTID-1 (GLP-1)
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
JP5887265B2 (ja) 2009-06-16 2016-03-16 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション Ｇｉｐ受容体活性グルカゴン化合物
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
CA2804755C (en) * 2009-08-14 2018-06-05 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
EP2495255A4 (de) * 2009-10-30 2013-05-15 Otsuka Chemical Co Ltd Glycosylierte form eines antigenen glp-1-analogs
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
EP2512503A4 (de) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Coagonisten des glucagon/glp-1 rezeptors
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2555791B1 (de) 2010-04-09 2017-11-01 Sinai Health System Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten
BR112012028707A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
CA2797095A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CN103124739B (zh) * 2010-05-17 2015-11-25 贝达药业股份有限公司 一种新胰高血糖素样肽类似物、组合物及其用途
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
CN102180963B (zh) * 2011-04-22 2014-06-25 中国药科大学 胰高血糖素样肽-1(glp-1)类似物及其应用
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2729157B1 (de) 2011-07-06 2019-01-16 The General Hospital Corporation Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
JP6352806B2 (ja) * 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
IN2014DN03093A (de) 2011-10-24 2015-05-15 Mannkind Corp
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
MX2014015558A (es) 2012-06-21 2015-03-05 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CN103087179A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087177A (zh) * 2012-11-30 2013-05-08 中国药科大学 一类长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087175A (zh) * 2012-11-30 2013-05-08 中国药科大学 新型长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087178A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
CN103087176A (zh) * 2012-11-30 2013-05-08 中国药科大学 长效化胰高血糖素样肽-1(glp-1)类似物及其应用
SG10201708090TA (en) 2013-03-15 2017-11-29 Mannkind Corp Microcrystalline diketopiperazine compositions and methods
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (de) 2013-08-05 2020-10-07 MannKind Corporation Insufflationsvorrichtung
CN104262481B (zh) * 2013-08-09 2018-02-09 天津药物研究院有限公司 一种侧链修饰的长效glp‑1类似物的制备方法及其应用
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CA2947982C (en) 2014-05-08 2022-11-29 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA55068A (fr) * 2014-10-24 2022-01-05 Merck Sharp & Dohme Co-agonistes des récepteurs du glucagon et du glp-1
US10688156B2 (en) 2015-02-09 2020-06-23 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
EP3302354B1 (de) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
PL3774862T3 (pl) 2018-04-05 2022-10-03 Sun Pharmaceutical Industries Limited Nowe analogi glp-1
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
SG11202103586UA (en) 2018-10-11 2021-05-28 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use
KR20210081376A (ko) 2018-10-30 2021-07-01 지아닝 리우 Glp-1 수용체 작용제 활성을 갖는 glp-1 폴리펩티드 및 그의 용도
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN115135305A (zh) 2020-02-18 2022-09-30 诺和诺德股份有限公司 药物制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE69129226T2 (de) * 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ATE265224T1 (de) 1998-02-27 2004-05-15 Novo Nordisk As Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO2000007617A1 (en) * 1998-07-31 2000-02-17 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6429197B1 (en) * 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
AU6479101A (en) * 2000-06-16 2002-01-02 Lilly Co Eli Glucagon-like peptide-1 analogs
US7271149B2 (en) * 2000-12-07 2007-09-18 Eli Lilly And Company GLP-1 fusion proteins
AU2002317599B2 (en) * 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
AU2010279305A1 (en) * 2009-08-07 2012-03-01 Perry Felix Method and apparatus for surface and subsurface sanitizing of food products in a cooking appliance using ultraviolet light

Also Published As

Publication number Publication date
PE20011363A1 (es) 2002-01-15
HUP0301212A2 (hu) 2003-08-28
US20060263849A1 (en) 2006-11-23
BR0111562A (pt) 2003-04-15
KR20030009537A (ko) 2003-01-29
HU229108B1 (en) 2013-09-30
PL360406A1 (en) 2004-09-06
CY1109061T1 (el) 2014-07-02
CA2412004A1 (en) 2001-12-27
MXPA02012203A (es) 2003-06-06
CZ20024088A3 (cs) 2003-05-14
PT1294757E (pt) 2007-02-28
ATE346093T1 (de) 2006-12-15
EP1695983A3 (de) 2007-02-21
HUP0301212A3 (en) 2004-09-28
DZ3388A1 (fr) 2001-12-27
CN100469791C (zh) 2009-03-18
SI1695983T1 (sl) 2009-08-31
AR031701A1 (es) 2003-10-01
EP1294757A2 (de) 2003-03-26
EG24755A (en) 2010-07-26
DE60124710D1 (de) 2007-01-04
EP1294757B1 (de) 2006-11-22
HRP20020996B1 (en) 2011-09-30
WO2001098331A3 (en) 2003-01-03
JP2004501162A (ja) 2004-01-15
NZ522330A (en) 2004-11-26
DK1695983T3 (da) 2009-05-18
ES2275685T3 (es) 2007-06-16
EP1695983A2 (de) 2006-08-30
HRP20020996A2 (en) 2004-02-29
NO20025949D0 (no) 2002-12-11
CA2412004C (en) 2010-12-21
CN1468258A (zh) 2004-01-14
WO2001098331A2 (en) 2001-12-27
SK287757B6 (sk) 2011-08-04
IL153453A0 (en) 2003-07-06
MY137350A (en) 2009-01-30
IL153453A (en) 2009-11-18
TWI321134B (en) 2010-03-01
CZ304002B6 (cs) 2013-08-14
KR100847615B1 (ko) 2008-07-21
JP4716641B2 (ja) 2011-07-06
EP1695983B1 (de) 2009-03-04
NO20025949L (no) 2002-12-11
DE60124710T2 (de) 2007-09-13
PL206302B1 (pl) 2010-07-30
US7084243B2 (en) 2006-08-01
NO330686B1 (no) 2011-06-06
DE60137876D1 (de) 2009-04-16
US20030220243A1 (en) 2003-11-27
ES2321439T3 (es) 2009-06-05
HU229208B1 (en) 2013-09-30
EA008837B1 (ru) 2007-08-31
SK17782002A3 (sk) 2003-07-01
EA200300026A1 (ru) 2003-04-24
HK1055121A1 (en) 2003-12-24
US7498308B2 (en) 2009-03-03
AU2001264791B2 (en) 2006-11-23
CY1105917T1 (el) 2011-04-06
DK1294757T3 (da) 2007-03-19
PT1695983E (pt) 2009-05-05
AU6479101A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
IS2932B (is) Fúlvestrant samsetning
EE200100132A (xx) Stent
EE200100304A (xx) Stent
DE60236093D1 (de) Entfernbarer stent
DE60116273D1 (de) Tabakverarbeitung
DE60000964D1 (de) Glaskeramik
NO20040198L (no) Dolastatin 10 derivater
NO20024890L (no) Implantat
NO20024906L (no) Antitumorale ecteinascidinderivater
PT1250321E (pt) Composicao de gliburida
ATA15802000A (de) Pinzette
DE60102050D1 (de) Glaszusammensetzung
DE60105696D1 (de) Eisenhaltige Proteinzusammensetzung
DE60116858D1 (de) Zusammensetzung
GB0023296D0 (en) Prestressing of components
DE50114951D1 (de) Stabilisatorzusammensetzung
DE60112000D1 (de) Handgelenktotalprothese
CU23064A3 (es) Conjunto implante dental-transportador
NO20021680D0 (no) Forbedret skriveprotese
ATE294812T1 (de) 16alpha-methyl oder ethyl substituierte oestrogene
DE60107312D1 (de) Feste Zusammensetzung
FR2803509B1 (fr) Prothese metatarso-phalangienne
DE50201746D1 (de) Prothese
DE60204472D1 (de) Reinigungszusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1695983

Country of ref document: EP